{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-23T06:29:35.792Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"ARQT\",\n \"company\": \"Arcutis Biotherapeutics, Inc.\",\n \"investigation_summary\": \"Arcutis is a commercial-stage dermatology company whose lead product ZORYVE (topical roflumilast) delivered 65% YoY revenue growth in Q1 2026 ($105.4M). The pipeline trigger was a Form 4 cluster — however, every single filing examined from the May 2026 window represents routine tax-withholding sells via pre-set 10b5-1 plans by the CEO (3,172 shares), CLO (8,256 shares), CFO (1,341 shares), CMO (684 shares), and a director (7,144 shares). Zero open-market purchases. The stock collapsed ~34% from its November 2025 high ($31.20) to $20.86 following Q1 earnings that beat top-line but showed a large EPS miss driven by R&D investment. Analysts cluster at $34–36 targets — meaningful upside vs current price, but the near-term setup lacks urgency: stock below both 50- and 200-DMA, no insider buying signal, next catalyst is August earnings. IV runs 67–68% ATM, creating a viable covered-call / strangle income structure on rallies.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\",\n \"strangle\"\n ],\n \"business_snapshot\": \"Arcutis Biotherapeutics commercializes ZORYVE (roflumilast), a topical PDE4 inhibitor for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis — across three dosage strengths (0.3%, 0.15%, 0.05%). The franchise generated $415M in TTM revenue growing 60% YoY with best-in-class 91% gross margins. Q1 2026 was the company's first quarter of positive operating cash flow ($27M), a pivotal inflection for what has been a pre-profitability biotech that just turned corner on unit economics. The company guided to $480–495M net product revenue for full-year 2026 (up from prior guidance raise). Key pipeline: an sNDA was filed April 2026 to extend ZORYVE cream 0.05% down to infants aged 3 months — a market of ~1 million children under age 2, where only one other topical non-steroidal agent exists. The AAD issued strong pediatric AD guidelines recommending ZORYVE in April 2026, reinforcing clinical positioning. Capital structure shows $224M cash vs $115M debt (net-cash positive), and the company has an ATM equity facility available.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 520000,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-05T20:00:00.000Z\",\n \"recent_eps_surprise_pattern\": \"Q4 2025 beat by +47%; Q3 2025 beat by +164% (turned profitable); Q1 2026 missed EPS estimate by -55% due to elevated R&D spend on pipeline expansion, but revenue beat by +6%\",\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"regulatory\",\n \"description\": \"sNDA filed April 2026 for ZORYVE cream 0.05% down to infants age 3 months with mild-to-moderate atopic dermatitis — ~1M addressable pediatric patients in the US, only one competing topical non-steroidal option.\",\n \"date_or_window\": \"FDA review expected Q4 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"guidance\",\n \"description\": \"Full-year 2026 net product revenue guidance reaffirmed at $480M–$495M despite stock drop after Q1. Company achieved first positive operating cash flow quarter.\",\n \"date_or_window\": \"Reaffirmed May 6, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Strong recommendation from American Academy of Dermatology for ZORYVE in pediatric AD guidelines — first-ever such designation.\",\n \"date_or_window\": \"April 22, 2026\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n ],\n \"directional_bias\": \"bullish\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 18.05,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 457.6,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 0.135,\n \"sotp_gap_pct\": null,\n \"narrative\": \"At $20.86, ARQT trades at an 18x forward P/E with 60% revenue growth — not cheap but not stretched relative to dermatology peers given the commercial inflection underway and analyst consensus at $34–36 (40-65% upside). EV/EBITDA is distorted by near-zero EBITDA from heavy R&D investment. The Q1 post-earnings selloff from ~$25 to ~$20 opened a meaningful gap, with fair value closer to mid-$20s based on fundamentals and the analyst consensus target reinforcing that range.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": 0,\n \"net_debt_to_ebitda\": -5.4,\n \"balance_sheet_grade\": \"A\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": false,\n \"rsi_14\": 43.1,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 20.86,\n \"ytd_return_pct\": -7.9,\n \"from_52w_high_pct\": 34\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-02-25\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm\",\n \"key_takeaways\": [\n \"FY 2025 product revenue $415.6M (+60% YoY); gross margin 90.9%; achieved first full-year positive operating cash flow of $3.5M; R&D investment $120M, SG&A $273M; Hengrui collaboration royalty stream from Chinese market (Huadong deal active since Nov 2025); AstraZeneca patent milestone payments ($4.75M in Q2 and Q4 2024); $224M cash vs $115M debt — net cash positive; significant customer concentration risk (no single customer >10%)\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-06\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm\",\n \"key_takeaways\": [\n \"Q1 2026 net product revenue $105.4M (+65% YoY); operating cash flow +$26.9M first positive quarter; R&D jumped to $30.6M vs $17.5M YoY due to pediatric AD development and foam expansion; SG&A $74.1M vs $64M YoY (commercial investment); net loss $11.3M vs $25.1M prior year — improving; inventory $37.4M up from $22.6M at Dec 2025 — stocking for demand growth; no debt maturity until June 2027\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-05-06\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000039/arqt-20260506.htm\",\n \"key_takeaways\": [\n \"Q1 earnings release; reaffirmed full-year guidance $480–$495M net product revenue\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-06-18\",\n \"2026-07-17\",\n \"2026-09-18\"\n ],\n \"iv_summary\": \"ATM IV at ~67–68% on 26-DTE June expiry; 22.5 strike call mid $0.50, ATM 20-strike call mid $1.98 — elevated premium environment enabling meaningful income generation on short-duration structures.\",\n \"notable_skew_or_flow\": \"Put skew is steep: 22.5 put IV (65.7%) nearly matches OTM call levels; 22.5 put ask spread of $0.10–$4.90 reflects illiquidity in deep-OTM puts; top open interest on calls at 22.5 strike (228 contracts) — modest upside hedging rather than directional aggression\"\n },\n \"competitive_landscape\": \"Dermatology topical anti-inflammatory market: ZORYVE competes with Opzelura (Incyte, JAK inhibitor with black box), Dupixent (systemic, expensive, injection-only), and generic corticosteroids. Arcutis's differentiated PDE4 mechanism avoids steroid side effects and JAK black-box warnings. In pediatric AD specifically, there are very few non-steroidal FDA-approved options — creating a strong moat for ZORYVE expansion down to infants.\",\n \"key_risks\": [\n \"No open-market insider buys — all recent Form 4 activity is tax-withholding sell under pre-set plans (bearish signal)\",\n \"Q1 EPS missed by -55% despite revenue beat; R&D spending accelerating (pediatric trial costs) could pressure near-term profitability\",\n \"Stock down ~34% from 52-week high with no technical inflection yet — below both DMAs, bearish MACD cross 11 bars ago\",\n \"Revenue concentration in single product ZORYVE creates binary risk on clinical/regulatory outcomes for label expansion\",\n \"Hengrui/Huadong China collaboration (royalty-based) faces Chinese regulatory and reimbursement uncertainty\"\n ],\n \"what_the_market_might_be_missing\": \"The sNDA filing for infant AD indication (3-month+ labeling) may be underappreciated: a market of 1 million US children under age 2 with only one other non-steroidal option represents a defensible pediatric franchise expansion that the August earnings narrative could shift. Separately, the Q1 selloff to $20 from ~$25 created a gap relative to analyst consensus at $34–36 — suggesting the stock may have overshot to the downside on near-term EPS concerns while long-run revenue trajectory remains intact.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"concentration\"\n ],\n \"sources\": [\n {\n \"label\": \"Q1 2026 earnings release / Q10-Q filing\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-announces-first-quarter-2026-200000402.html\"\n },\n {\n \"label\": \"sNDA infant AD submission\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-submits-supplemental-drug-application-120000919.html\"\n },\n {\n \"label\": \"AAD pediatric guideline recommendation\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/arcutis-zoryve-roflumilast-cream-receives-120000398.html\"\n },\n {\n \"label\": \"Form 4 — CEO Watanabe sell (tax withholding)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000180106126000003/xslF345X06/wk-form4_1778105161.xml\"\n },\n {\n \"label\": \"Form 4 — CLO Matsuda sell (tax withholding + plan)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1787306/000179867926000002/xslF345X06/wk-form4_1778110801.xml\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-23T06:30:38.569Z", "raw_content": "The dossier is for ARQT (Arcutis Biotherapeutics).\nScout's verdict: `range_bound_or_income`.\nStructure hints: `cc`, `strangle`.\nMarket cap: Not explicitly given, but it's a commercial-stage biotech with $415M revenue, $20.86 price. Likely mid-cap, but let's check `risk_class` criteria. I'll assume `core` or `asymmetric` based on market cap. Wait, I need to calculate or infer market cap. If price is ~$20 and revenue is $400M, market cap is probably around $3-4B. Let's assume `core` (> $5B) or `asymmetric` (≤ $5B). I'll stick to the rubric's thresholds. Actually, the prompt says \"choose one based on the dossier's market_cap field\", but it's missing. I will infer it's likely `core` or `asymmetric`. I'll just score it first.\n\nScoring:\nA. Smart-Money Cluster: 0 pts. (No insider buys, material insider selling > $500k. Penalty: -10 pts? Wait, penalty is if material insider SELLING > BUYING in dollars. Here selling is $520k, buying is $0. So -10 pts. But min is 0. So 0 pts.)\nB. Options Flow / UOA: 0 pts. (IV is elevated 67-68%, but no whale call blocks, steep put skew, modest OI. No bullish IV skew. 0 pts.)\nC. Catalyst: 10 pts? Next earnings Aug 5 (within 90 days). But EPS surprise pattern: Q4 beat, Q3 beat, Q1 missed. Not >0% for last 4 quarters. So 0 for that.\nGuidance raise: Reaffirmed guidance, not raised. 0 pts.\nNamed catalyst: sNDA filed April 2026 (FDA review Q4 2026) - not in horizon? Horizon is usually 90d. AAD guidelines in April - already happened.\nSo Catalyst score: 0 pts. (Maybe 5 pts for guidance raise? It says \"reaffirmed\", not raised. I'll give 0.)\nWait, rubric says: \"5 pts: recent guidance raise (last 90 days)\". It says reaffirmed. So 0.\nCatalyst: 0.\nD. Mispricing: 0 pts. Forward P/E 18.05, sector median null. EV/EBITDA 457.6. FCF yield 0.135%. SOTP null. 0 pts.\nE. Quality: 0 pts. ROIC null, gross margin trend 0, net debt/EBITDA -5.4 (net cash positive, but ratio is negative due to cash > debt? Actually net debt is negative, so debt/EBITDA is negative. Rubric says ≤ 2x or net cash. It is net cash. +5 pts? I'll give 5 pts for net cash positive balance sheet.)\nF. Momentum/Technical: 0 pts. Below both DMAs, RSI 43.1, no MACD cross. 0 pts.\n\nTotal Score: ~5 pts.\nAnti-signal gates: \"dilution\", \"concentration\". The dossier says \"significant customer concentration risk (no single customer >10%)\" in 10-K takeaways, but anti_signals_present says \"concentration\". Usually concentration >30% is the gate. I'll treat it as a minor flag, but the score is already very low.\nThe dossier clearly states: \"no insider buying signal\", \"stock below both DMAs\", \"IV elevated\", \"verdict: range_bound_or_income\".\nGiven the low score and the explicit lack of long thesis, this is a clear SKIP.\nI will output the skip JSON.\n\nLet's double check scoring rubric for E: \"5 pts: net debt / EBITDA ≤ 2x (or net cash)\". It says net cash positive. So +5.\nTotal: 5.\nRisk class: I'll assume asymmetric or core, doesn't matter since < 60.\nReason: \"Lacks insider support, technicals are broken, and no near-term catalyst beyond August earnings; elevated IV only supports an income structure, not a directional thesis, and the dossier flags concentration/dilution risks that outweigh the setup.\"\n\nWait, should I check if an income structure (CC or strangle) is viable enough to publish? The prompt says: \"OPTION B (skip) IS THE EXPECTED DEFAULT... Most dossiers should return { skip: true }... Mediocre publishes burn Devil's Advocate budget\". The score is 5. It's a skip.\n\nI will generate the skip JSON.\nScore breakdown:\nsmart_money: 0\noptions_flow: 0\ncatalyst: 0\nmispricing: 0\nquality: 5\ntechnical: 0\nTotal: 5.\n\nCheck rubric for catalyst: \"10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\" -> fails.\n\"8 pts: pending product launch / FDA / contract milestone in horizon\" -> sNDA filed April, FDA review Q4. Not in 90d horizon.\n\"5 pts: recent guidance raise\" -> reaffirmed, not raised.\nSo 0.\n\nCheck mispricing: 0.\nCheck quality: 5 (net cash).\nCheck technical: 0.\nCheck smart money: 0.\nCheck options flow: 0.\nTotal 5.\n\nSkip JSON format:\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"Score is critically low due to zero insider buying, broken technicals, and no near-term catalyst beyond August earnings. While IV is elevated enough for an income trade, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes a long or asymmetric thesis unjustified.\"\n}\nWait, the prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" This applies to PROCEED. For SKIP, it just says output exactly the skip JSON.\n\nI will produce the skip JSON.\nOne minor thing: `quality` score: net debt/EBITDA is -5.4. The rubric says \"5 pts: net debt / EBITDA ≤ 2x (or net cash)\". Since it's net cash positive, I'll give 5.\nTotal 5.\nAll good.\nProceed. \nOutput matches requested format.\nNo extra text.\nDone. \nLet's verify the exact JSON structure for skip.\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"...\"\n}\nMatches perfectly.\nI will generate it. \nSelf-Correction/Refinement during thought: \nCould the strangle/CC be viable? The prompt says \"OPTION B (skip) IS THE EXPECTED DEFAULT... Mediocre publishes burn Devil's Advocate budget\". Score 5 is way below 60. It's a hard skip.\nI will output the skip JSON. \nProceed. \nOutput Generation. \n[Done] \n```json\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.\"\n}\n```\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will strip the markdown fences.\nReady. \nProceeds. \nOutput matches exactly. \nFinal Check of the prompt: \"IF YOU SKIP — output exactly: { ... }\"\nAll good. \nOutput Generation. \n(Self-Correction/Note during generation prep: I should ensure the JSON is strictly valid and matches the schema exactly.)\nScore breakdown keys match. Reason is 1-2 sentences. Score is 5. Skip is true.\nDone. \nProceeds. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 5,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 0,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 0\n },\n \"reason\": \"Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.\"\n}", "tool_calls_total": 0, "walltime_ms": 62778, "stop_reason": "stop", "completed_at": "2026-05-23T06:30:38.570Z" }